What changed from existing technology?
This study talks about using math and data to make cancer drug development better. It shows how combining different types of information can help make smarter decisions when creating new cancer treatments.
The study introduces quantitative medicine as a new approach to improve decision-making in oncology drug development by integrating various types of data and models.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
OpenAlex author affiliations: Genentech
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
- 장기·실사용 검증 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This approach could help pharmaceutical companies make more informed decisions during drug development, potentially reducing the high failure rate in oncology drug development.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.
Evidence and sources
View paper and author affiliations
Open original researchHarnessing Quantitative Medicine to Advance Oncology Drug DevelopmentClinical and Translational Science · Published 2026-09-29 ↗Author institutions and listed legal entities are separated; only verified exchange and ticker data is linked.